Evercyte bringing range of offers to ToxExpo 2017
Press Release | Evercyte GmbH
FEBRUARY 28, 2017
Vienna, Austria: – Innovative biotech manufacturer Evercyte will return to the highly respected Society of Toxicology meeting, ToxExpo, in Baltimore, Maryland, with a range of new services based on its expertise in human telomerase immortalized cells.
At ToxExpo 2017, Evercyte will be featuring a range of new offers and recently introduced services based on its capability to produce high quality cells that comply with Good Cell Culture Practice (GCCP) standards.
Immortalized human podocyte
Along with Austrian chocolates, the Evercyte stand at Booth 2566 will be offering special show-only discounts of 20% on all products and services purchased at the meeting or within one week of the event’s closing date, March 16.
Available products and services now include:
- A human podocyte cell line immortalized by telomerase that provides an important kidney toxicology model to complement Evercyte’s existing successful proximal tubular cell line RPTEC/TERT1 for kidney toxicity studies in vitro
- Human bronchial epithelial cells (HBEC3-KT) immortalized by telomerase that use well differentiated cells as model systems to study lung disease / cancer and toxicology
- Gene editing of human primary like cells using CrispR/Cas9 and RPTEC/TERT1 cells as an example that can be extended to any gene deletion, gene or reporter insertion
- A new service for generating customer tailored human immortalized cells differentiated though cell type, donor and gene editing
- Capability to generate induced pluripotent stem cells (iPSCs) from human urine in a fully non-invasive way
- A service for establishing cell based assays, with GMP assays available with partner labs
- Availability of microRNAs in biofluids like blood, urine, etc., for use as liquid biopsy toxicology biomarkers
In-vitro cell based assays
“We made the decision to return to ToxExpo after the great success and interest we attracted with our initial appearance at the Society of Toxicology New Orleans meeting last year,” said Dr. Regina Grillari, Evercyte’s Chief Technology Officer.
“At Tox17 we will be reaching out to academics and scientists in pharmaceutical, chemical and cosmetic industries from more than 50 countries with particular focus on scientists in CROs offering in vitro cell based assays. We will be presenting new products and services, recruiting new customers, caring for our regular customers and identifying potential partners for H2020 and other projects,” Regina Grillari added.
Dr. Johannes Grillari, Evercyte’s Chief Scientific Officer, an expert in cell and molecular biology, will be at the booth throughout the meeting to discuss Evercyte products and services.
High karyotypic stability
“Human telomerase immortalized cells present the most robust and reproducible system for cell based assays and in-vitro toxicology due to unlimited cell supply,” said the Evercyte CSO.
“Telomerase maintains the primary key functionalities of the cells unchanged so that karyotypic stability is therefore high. These cells are the only surrogates with primary cell characteristics that can be gene edited for functional studies and fast reporter gene assays using targeted insertion of genes by CrispR/Cas9. This enables orthogonal screenings in phenotypic drug screening or target screenings in isogenic human cell lines. Along with functional in vitro studies for adverse outcome pathways (AOPs),” said Johannes Grillari.
Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; including primary/normal cells; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from immortalized or normal stem cells.
Recently, Evercyte has become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.
Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population by systematically establishing and commercializing relevant cell type specific model systems from donors of different genetic backgrounds.
About ToxExpo 2017
ToxExpo™ is the annual meeting of the US Society of Toxicology that brings together toxicologists from around the world to share research and expertise and find new collaborators.
The 56th Annual Meeting, ToxExpo 2017, is a five-day event, opening March 12 at the Baltimore Convention Center in Maryland. It is expected to attract some 6,800 attendees and more than 350 toxicology-related companies and organizations from some 50 countries.
The 2017 meeting will feature more than 160 scientific sessions, featuring nearly 2,500 abstracts, as well as a co-hosted exhibition.
The event is organized by the Society of Toxicology, based in Reston, VA. More information at: http://www.toxicology.org/events/am/AM2017/
Birgit Marckhgott, Project management and Business Development, Evercyte GmbH
Tel: +43 699 107 09 401